137 related articles for article (PubMed ID: 9096672)
21. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
22. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
[TBL] [Abstract][Full Text] [Related]
23. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.
Koot D; Cromarty D
Drug Deliv Transl Res; 2015 Jun; 5(3):257-67. PubMed ID: 25795051
[TBL] [Abstract][Full Text] [Related]
24. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
25. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
26. Preparation and evaluation of paclitaxel-containing liposomes.
Holvoet C; Vander Heyden Y; Lories G; Plaizier-Vercammen J
Pharmazie; 2007 Feb; 62(2):126-32. PubMed ID: 17341033
[TBL] [Abstract][Full Text] [Related]
27. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo.
Hassan S; Dhar S; Sandström M; Arsenau D; Budnikova M; Lokot I; Lobanov N; Karlsson MO; Larsson R; Lindhagen E
Cancer Chemother Pharmacol; 2005 Jan; 55(1):47-54. PubMed ID: 15565443
[TBL] [Abstract][Full Text] [Related]
31. Embryotoxicity of free and liposome-encapsulated taxol in the chick.
Scialli AR; DeSesso JM; Rahman A; Husain SR; Goeringer GC
Pharmacology; 1995 Sep; 51(3):145-51. PubMed ID: 7501699
[TBL] [Abstract][Full Text] [Related]
32. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
33. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies.
Zhang JQ; Zhang ZR; Yang H; Tan QY; Qin SR; Qiu XL
Pharm Res; 2005 Apr; 22(4):573-83. PubMed ID: 15846465
[TBL] [Abstract][Full Text] [Related]
34. DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy.
Jang E; Son M; Jang J; Lee IH; Kim S; Kwon T; Jeon YH; Koh WS; Kim KS; Kim SK
PLoS One; 2019; 14(11):e0225095. PubMed ID: 31743348
[TBL] [Abstract][Full Text] [Related]
35. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
36. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
Devalapally H; Shenoy D; Little S; Langer R; Amiji M
Cancer Chemother Pharmacol; 2007 Mar; 59(4):477-84. PubMed ID: 16862429
[TBL] [Abstract][Full Text] [Related]
37. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
[TBL] [Abstract][Full Text] [Related]
38. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
39. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
40. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
